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Background: Numerous Plasmodium falciparum antigens elicit humoral responses in humans living in endemic areas.
Use of multiplex assays is a convenient approach to monitor the antibody response against multiple antigens, but to
integrate multiplex assay-derived data with datasets, generated previously using ELISA, comparative studies are needed.
This work compares antibody responses to two P. falciparum antigens monitored using both technologies.
Methods: The IgG response against the merozoite surface protein-1 PfMSP1p19 and the PF13-DBL1α1 domain of the P.
falciparum Erythrocyte Membrane Protein1, expressed by the rosette-forming parasite 3D7/PF13 (PF13), was investigated
using ELISA and a MAGPIX®-Luminex duplex assay. Archived plasma samples collected before the rainy season from 217
villagers living in Ndiop, a Senegalese meso-endemic setting, were studied. ROC analysis was used to define the optimal
antibody measure readout. Association of antibody levels with protection against clinical malaria was analysed using
Poisson regression in a retrospective study from active case detection records performed during the 5.5-month
transmission season that followed blood sampling.
Results: There was a strong positive correlation (P <10−3) between ELISA and MAGPIX®-Luminex-MFI (median
fluorescence intensity) values for antibody to PfMSP1p19 (rho = 0.78) and PF13-DBL1α1 (rho = 0.89), with a similar degree
of concordance in all age groups. Antibody levels to both antigens were high but displayed a different age-associated
pattern. Independent age-adjusted Poisson regression analysis showed a significant association with protection only for
IgG responses to MSP1p19 (P <0.01 RR = 0.71 [0.53-0.93]) measured by ELISA.
Conclusion: The individual ELISA and duplex-MAGPIX assays provide a concordant evaluation of age-associated antibody
responses to MSP1p19 and PF13-DBL1α1, irrespective of the formulation of antibody levels (values, ratios or ROC-adjusted
figures) but do diverge with regard to the association of antibody levels with clinical protection in age-adjusted models.
This may reflect incomplete overlap of the epitopes presented in the two formats. Further development for multiplex
assessment of antibody responses to a larger panel of antigens with the robust and cost effective MAGPIX®-Luminex
technology is warranted.
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Malaria is a major threat in tropical and subtropical
regions, with nearly 50% of the world population exposed
to infective bites by anopheles mosquitoes [1]. Malaria
parasites expose a large array of antigens both at the pre-
erythrocytic and erythrocytic stages. Although it has been
clearly demonstrated that antibodies play a crucial role in
immune protection to malaria [2,3], the precise antigenic
targets and mechanism of protective immunity remain
uncertain [4]. Numerous studies have attempted to use
the antibody response to specific parasite antigens to evalu-
ate exposure to malaria in both immune and naive popula-
tions. Responses to some antigens were shown to partially
correlate with clinical protection in immune or vaccinated
populations [5], but no consensus has emerged yet.
Multiple studies [6,7] investigated antibody responses in
endemic populations using the enzyme-linked immuno-
sorbent assay (ELISA). This technique requires separate,
independent testing for each individual antigen, which is
labour intensive and differs from the in vivo situation with
multiple parasite antigens exposed simultaneaously. More-
over, the increasing number of newly discovered antigens
[8] calls for implementation of multi-target detection
capacity either for analysing the immune signature of
infection or for pre- or post-vaccination investigations [9].
Furthermore, often only small quantities of blood are
ethically available for analysis in malaria-endemic popula-
tions, including neonates or finger-prick samples from
adults. Therefore, a reliable assay that measures antibody
responses simultaneously to several antigens with a few
microlitres of blood would be highly advantageous.
Multiplex immune detection assays, which measure mul-
tiple antigens simultaneously, can be performed in several
formats using micro-arrays [10-12] or Luminex™ (Luminex
Corp, Austin, USA) xMAP fluorescent-coded beads, where
each individual antigen is covalently linked to specific
colour-coded microspheres such that the reading device
can classify each bead set separately. Luminex™ instrumen-
tation generally quantifies laser-induced fluorescent signals
from each bead using flow cytometric technology. This
methodology has recently been used for multiplex detec-
tion of malaria antigens [13-16]. A convenient recently
developed alternative is the MAGPIX® technology (Millipore,
MA, USA), which uses colour-coded magnetic beads dis-
played in a monolayer, which are detected with a light-emit-
ting diode (LED) instead of laser system and imaged using a
charge-coupled device (CCD) camera. This platform consid-
erably reduces the costs of the multiplex approach since
antigen is immobilized on a much smaller surface area
compared to microplate wells, and sample volumes are
reduced compared to ELISA. However, there are important
differences between bead-based assays and ELISA. The
beads bind antigen via covalent cross-linking of protein
lysine residues to bead carboxylic acids using a carbodiimidecompound, as opposed to ELISA where antigen coating of
the well surface results from hydrophobic interactions with
the plastic plate. Thus, different protein residues interact
with the supports in the two methodologies, possibly modi-
fying the exposure of antigen epitopes.
The present study was designed to compare the
MAGPIX®-Luminex and ELISA approaches by measur-
ing antibody responses to two recombinant Plasmo-
dium falciparum antigens, the baculovirus-expressed
PfMSP1p19 derived from merozoite surface protein 1
[17], and PF13, the NTS-DBL1α _domain of P. falciparum
Erythrocyte Membrane antigen 1 of the PF13_0003 anti-
gen expressed by the rosette-forming 3D7/PF13 clone
[18]. A retrospective analysis was conducted on blood
samples collected before the rainy season from individuals
living in the village of Ndiop, a meso-endemic setting
located in southern Senegal. Prevalence and levels of anti-
body response were assessed using both methodologies and
the relationship of antibody responses with morbidity, as
measured by active case surveillance during the following
5.5 months, was explored.
Methods
Study area, study design, ethic statements and
procedures
The study was carried out in Ndiop, a Senegalese village
with seasonal transmission where a long-term longitudinal
survey designed to study acquisition and maintenance of
natural immunity has been carried out over more than
20 years [19-22]. The project protocol and objectives were
carefully explained to the assembled villagers, and in-
formed consent was obtained from all participants or their
parents or guardians on a voluntary consent form written
in both French and in Wolof, the local language. The
protocol was approved by the Senegalese National Health
Research Ethics Committee. An agreement between Fon-
dation Institut Pasteur de Dakar, Institut de Recherche
pour le Développement (IRD) and the Ministère de la
Santé et de la Prévention of Senegal defines all research
activities in Ndiop. The project is re-examined annually by
the Conseil de Fondation de l’Institut Pasteur de Dakar and
approved by the assembled village population. Informed
consent is individually renewed from all subjects; anyone
can withdraw from the study and the follow-up procedure
at any time.
Active clinical surveillance was carried out during the
5.5-month transmission period of year 2002, such that each
villager was monitored daily at home and blood films were
analysed in case of fever [20,21]. The protocol included
recording all febrile episodes and controlled use of anti-
malarial drugs by the medical staff. A malaria attack was
defined as an association of symptoms indicative of malaria
with parasitaemia >30 trophozoites/100 leukocytes. Anti-
malarial drugs were administered under supervision of the
Perraut et al. Malaria Journal 2014, 13:410 Page 3 of 11
http://www.malariajournal.com/content/13/1/410medical staff following diagnosis of clinical malaria. Malaria
attacks were considered independent if separated by more
than 15 days.
The cumulative entomological inoculation rate (EIR)
was monitored as described [23]. The estimated EIR for
the year 2002 transmission season was 17.9 infective
bites/individual from the beginning of September to the
end of November, with no detectable transmission in July,
August and December 2002.
Antigens
The procedure for protein expression and purification of the
recombinant PF13 (amino acids 1–486 of PF13_0003, with
all predicted N-glycosylation sites mutated to NxA and a C-
terminal hexa-His tag) has been described [24]. Soluble
recombinant protein corresponding to P. falciparum
MSP1p19 was produced in the baculovirus/insect cell
expression system and purified by metallo-affinity chro-
matography as described [17].
ELISA
PF13 and PfMSP1p19 were coated on Immulon-4 plates
(Dynatech) at 1 and 0.5 μg.mL−1, respectively. Sera were
used at a 1/200 dilution. All other procedures were as
described [24,25]. Each plate included two positive controls:
a pool of human Immune IgG (kind gift from Prof M
Hommel) and a pool of 30 sera collected in 2000–2 from
immune adults from Dielmo, a holoendemic village located
5 km apart from Ndiop [21,22]. The negative naïve control
was a pool of non-immune sera from blood donors living in
France. For inter-assay comparisons, results were expressed
as absorbance ratios corresponding to OD-sample/OD-
naïve. Positive responders were individuals with an absorb-
ance ratio over 2 corresponding to the mean OD of naïve
controls +2SD.
Coupling of antigens to beads
The covalent coupling of PF13 and PfMSP1p19 to carbox-
ylated magnetic Luminex microspheres by the carbodiimide
reaction (Luminex Corp, Austin, USA) was done using the
xMAP® Antibody Coupling Kit (ref 40–50016, Luminex
Corp, Austin, USA) according to the manufacturer’s in-
structions. Briefly, 2.5×106 beads from colour regions 12
and 13 were resuspended after sonication and rotative
mixing in microcentrifuge reaction vials and washed twice
before adding the activation buffer. The working volume
was 500 μL; all washing steps or buffer changing were done
after 1–2 min centrifugation at 8,000 × g and 1-min
magnetic pelletting using the Luminex® Magnetic plate
separator (Luminex Corp, Austin, USA), followed by
30-sec vortexing and 30-sec sonication in water-bath
sonicator to optimally disperse the beads. Ten μL
carbodiimide hypochloride (EDC) was then added and
incubated 20 min with a vortexing step after 10 min.After three washes, 5 μg antigen per million beads (amount
determined from prior optimisation procedure, manu-
script submitted) was added in the activation buffer in a
final volume of 500 μL and kept under rotation mixing
(15–30 rpm) in the dark for two hours. After three steps
of pelletting and washing, the supernatant was removed
and replaced by 1 mL wash buffer and kept in the dark at
2-8°C after another vortexing and sonication step to
disperse the microspheres. The final count of beads using
cell counter showed 96% recovery (2.4×106 beads). Efficient
coupling of antigen was controlled using mouse anti-His
tag antibody. The coupled microspheres were kept in the
washing/storage buffer at 4°C in the dark until use.
Bead-based assay for IgG antibodies to PF13 and
PfMSP1p19
The custom magnetic bead-based MAGPIX®-Luminex
assay (MBA), performed in a dimly lit room, was adapted
to parallel the working steps used in the standard ELISA
technique. The duplex mixture of PF13 and PfMSP1
microspheres was prepared and kept in an opaque vial;
2.5 μL aliquots containing 3,000 beads per antigen were
dispensed to individual wells of a white, polystyrene,
opaque, round-bottomed microtitre plate (Ref. 103977741,
Fisher Scientific, Illkirch, France); 100 μL plasma diluted 1/
200 in PBS Tween 0.01% BSA 1% (PBSB) was added in
duplicate wells, mixed and incubated with the beads
protected from light on a microplate shaker (IKA®MTS,
Wilmington, NC, USA) at 350 rpm for 45 min. Removal of
plasma and two washing steps of magnetic-pelletted beads
with 100 μL PBSB were done, 100 μL phycoerythrin-
labelled goat anti-human IgG diluted 1:500 (gamma- chain
specific, F(ab’)2 fragment-R-phycoerythrin (P-8047, Sigma,
St. Louis, MO, USA) in PBSB was then added to each well
and incubated in the dark, with shaking at 350 rpm for
45 min. This step was followed by two careful washes of
the plates as above, with 100 μL/well of PBSB. The beads
were then resuspended in 120 μL PBSB and analysed on a
Multiplex MAGPIX system (Millipore, MA, USA) using
the xPONENT 4.1 software for acquisition and assay
design. The reader was set to read a minimum of 50 beads
of unique fluorescent signature per region with the output
of median fluorescence intensity (MFI) per sample as
stated by manufacturer’s instructions. Antibody response
was considered positive for MFI values if the signal was
greater than twice the background signal [mean of 6
determinations +2 SD of the negative pool of non-
immune control sera].
The MFI ratio was calculated as MFI sample/MFI naïve
(MFI naïve being the mean MFI signal +2 SD of naïve
controls), and as for ELISA, responders were those with
MFI ratio > 2. The prevalence of positive antibody responses
was also calculated using receiver operating characteristic
(ROC) curve procedure (see below).
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Comparisons for categorical variables were done using the
Fisher exact test, continuous variables of antibody responses
were analysed using the Kruskal Wallis and the Spearman
rank correlation test for non-normally distributed data. The
ROC (Receiver Operating Characteristic) curve analysis was
used to determine the best threshold point for optimal posi-
tivity according to the two methods. P values <0.05 were
considered significant.
A Poisson regression model was used to analyse the rela-
tionship between antibody responses and the incidence of
malaria attacks during the follow-up period. Antibody
responses to MSP1 and PF13, expressed as OD or MFI,
OD or MFI ratios or categorized into responders vs. non-
responders, were analysed as monoplex and duplex re-
sponses. For analysis, the age stratification was based on
the age-dependent distribution of the parasite and clinical
data determined for this site [20]. Malaria attacks were
considered independent if separated by more than 15 days.
For each villager, the follow-up time was calculated as the
number of days actually spent in the village during the
5.5 months of follow-up. Villagers who were away from
the village for more than 30 days during the follow-up
period were excluded from the malaria incidence analysis.
Follow-up time was also adjusted for individuals who
received anti-malarial treatment, by excluding a period of
eight to 15 days after the first day of treatment (eight days
for quinine, ten days for chloroquine and 15 days for
sulphadoxine-pyrimethamine treatments, respectively).
Statistical analyses were performed with Egret 3.01®, R
and Statview 5.0® softwares.Results
Characteristic of the cohort
Cross-sectional blood sampling was done for 217 healthy
villagers aged 3.4 to 76.9 years. Five age classes were
defined for analysis, i.e., <five years, five to nine years, ten to
14 years, 15–29 years, and >30 years. Detailed characteristics
of the cohort are summarized in Table 1. At the time of
sampling in July, 19% of the villagers had a microscopically
positive blood smear. Individuals recruited for the study hadTable 1 Characteristics of the cohort from Ndiop analysed in
Age groups (y
<5
Number of villagers 11
Sex ratio F/M 5/6
Median age (years) 3.9
No Indiv. Hb AA/AS/AC 8/3/0
% parasitemic individuals* 9%
Overall number of clinical attacks during follow up (%) 24 (10%)
*Individuals with positive blood smear on the day of blood withdrawal.not used anti-malarial medication for at least four weeks
prior to blood sampling.
ELISA and magnetic-beads MAGPIX®-Luminex assay
(MBA)
ELISA and MBA were done independently on each blood
sample. MBA were performed during three consecutive days
within one week following antigen coupling. MBA showed
excellent specificity with very low MFI results on multiple
naïve or negative individuals (MFI from 85 to 120, with
mean values of 95, 105 for MSP1p19 and PF13, respectively).
Efficient coupling of antigen was controlled using mouse
anti-His tag antibody (MFI above 10,000 for each region)
and high MFI signal were observed when using mouse
monospecific control antibodies (MFI above 8,000).
For the analysis of antibody responses using the two
techniques, several read out formulations were used for
antibody levels, namely observed OD and MFI values as
well as calculated OD- or MFI-ratio, as values and/or ratios
are commonly used in seroepidemiology. Their different
dynamic range provide a different appreciation of the data.
These two types of formulations were used to analyse
response levels by age group and their association against
subsequent clinical malaria in order to identify the best
read out to use in further studies. Seroprevalence was
calculated from OD- or MFI-ratio or ROC adjusted results.
General concordance between duplex MBA and
monoplex ELISA estimates of antibody responses
As illustrated in Figure 1, there was a significant (P <10−3)
positive correlation between MFI and OD values for anti-
body responses to PF13 (Figure 1a, rho = 0.89) and to
MSP1p19 (Figure 1b, rho = 0.78) monitored by the two
methodologies. When including only positive responders
(ie, individuals with OD-ratio >2), the correlation remained
significantly positive (P < 10−3), rho = 0.80 and 0.65 for
PF13 and MSP1p19, respectively. When stratifying by age
group, antibody levels showed a similar degree of concord-
ance of the two techniques in all age groups (<5, 5–10, 10–
15, 15–29, and ≥30 years) for PF13 (rho = 0.89, 0.90, 0.83,
0.89, 0.85, respectively) and MSP1p19 (rho = 0.97, 0.68,
0.82, 0.80, 0.72, respectively).this study
ears)
5-9 10-14 15-29 ≥30 Overall
39 34 65 68 217
19/20 17/17 39/26 36/32 116/101
7.3 12.4 20.1 43.9 22.8
33/3/3 32/1/1 55/10/0 54/13/1 182/30/5
21% 38% 16% 11% 19%
108 (47%) 51 (22%) 33 (16%) 13 (6%) 229 (100%)
Figure 1 Correlation between the results from ELISA and duplex MBA using the Spearman’s rank correlation test and ROC curves
calculation output. ELISA OD (Y axis) vs MFI (X axis) values are plotted for IgG responses against PF13 (a) and MSP1p19 (b). The regression line
indicates a significant correlation (P <10−3) of antibody responses measured by two methods for PF13 (rho = 0.89) and for MSP1p19 (rho = 0.78). The
ROC curves plotting specificity vs sensitivity of the two methods, used to calculate the best cut-off point, are shown for PF13 (c) and MSP1p19 (d).
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off points of optimal sensitivity, specificity of MFI vs
ELISA. Plotting of the curve is shown in Figure 1c for
PF13 with a cut-off at MFI = 214 (sensitivity = 86%, speci-
ficity = 87%) and in Figure 1d for MSP1p19 where cut-off
was at MFI = 114 (sensitivity = 83%, specificity =77%).
Prevalence of antibody responses against PF13 and
MSP1p19
A high prevalence of IgG responses against both antigens
was observed both using ELISA and MBA as well using the
ROC-defined thresholds (Table 2). Seroprevalence to PF13
measured by the two techniques did not differ significantly,
71 vs 65% of responders at the village level, by ELISA and
MBA, respectively. Using the ROC-corrected calculation,
seroprevalence was not modified compared to MFI ratios
output in all age groups. Seroprevalence to PF13 determinedby ELISA was low in children under five years, it increased
quite significantly in the five to nine years group , further
increased reaching 94% in the ten to 14 years group, and
decreased in older individuals (Fisher exact test, P < 0.01).
Seroprevalence calculated from MFI-ratios and ROC-
adjusted values was lower than estimated from ELISA data.
The age distribution also showed a sharp increase during
childhood. Compared to ELISA, there was a smaller, non-
significant increase in the ten to 14 year-old children, and
values plateaued thereafter.
Seroprevalence to MSP1p19 measured by ELISA was
also high, reaching 74% at the village level by ELISA and
estimated at 56 or 67% by MFI-ratios or ROC-adjusted
MFI, respectively. Prevalence calculated from MFI-ratios
was consistently lower in all age classes compared to
ELISA OD-ratios and ROC-adjusted MFI (P <0.01).
When considering the MFI optimal threshold defined by
Table 2 Prevalence of IgG antibody responses against MSP1p19 and PF13 according to different formulations of ELISA
and duplex MBA data
Villagers Antibody responses to PF13 Antibody responses to PfMSP1p19
Age-class No OD-ratio* %resp. MFI-ratio* %resp. %ROC** OD-ratio %resp. MFI-ratio %resp. %ROC
<5y 11 1.9 27% 2.3 18% 18% 3.7 64% 3.4 36% 36%
5-9y 39 6.0 51% 8.7 59% 54% 3.6 49% 3.7 33% 56%
10-14y 34 10.3 94% 12.5 71% 71% 5.1 74% 5.9 59% 74%
15-29y 65 9.4 74% 11.1 68% 68% 6.6 80% 6.5 57% 63%
≥30y 68 8.7 74% 8.6 72% 72% 7.5 85% 6.9 69% 79%
all 217 8.3 71% 9.7 65% 65% 5.9 74% 5.8 56% 67%
*Mean values of antibody responses measured with ELISA and duplex magpix test.
**Incidence of responders using optimal threshold defined by ROC analysis.
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classified as positive and the percentage of responders
increased to intermediate values between those calculated
from ELISA OD-ratios and MFI-ratios. As shown in
Table 2, seroprevalence estimated from ELISA OD-ratios
was substantial in the < five years age group and increased
in the > nine years old children, and adults. Intriguingly,
seroprevalence tended to be lowest in the five to nine years
old children, this difference being significant compared to
the 15–29 or ≥30 years age groups (Fisher exact test, P <
0.01). Such an age-associated profile was not observed for
antibodies monitored using MBA.
Comparison of age distribution of antibody levels
estimated using ELISA and MBA
For the two antigens, there was a low but significant
relationship between age and antibody responses measured
by ELISA and MBA (Spearman rank test, Rho = 0.17 to 0.21,
P <0.05).
The age-stratified profiles of mean IgG responses to both
antigens are shown on Figure 2. Very similar age-stratified
profiles were observed using the two methodologies, and
they were antigen-specific. There was a sharp increase of
antibody levels to PF13 after the age of five years, peaking
significantly in the ten to 14 year old children, (Mann–
Whitney rank test, P <0.01), and slightly decreasing in the
older age group. For MSP1p19 Ag, antibody levels were
moderate in the two younger age groups (<5 and 5–9 y)
and continuously increased with age. The difference was
significant between the younger age group and the oldest
one in all cases. Importantly, the age profile was independ-
ent of the read out formulation. Figure 2 shows the OD-
ratio and MFI-ratio data, age-distribution with OD and
MFI values are shown in Additional file 1.
Importantly, there was no significant relationship
between the magnitude of antibody responses to PF13
and to MSP1p19 with haemoglobin phenotype of indi-
viduals (AA vs AS). Moreover, detectable P. falciparum
asymptomatic carriage, as evidenced by thick blood
smear count, had no impact on antibody values.Relationship between antibody responses and occurrence
of clinical attacks
A total of 217 individuals were considered for longitudinal
follow-up period (1 July-31 December); 229 clinical malaria
episodes were recorded. The mean incidence rate of
malaria attacks (number of malaria attacks per 100 person-
months) was 17.7 (95% CI: [14.6-20.9]). It differed between
age groups (Kruskal-Wallis test, P <0.01), with a higher
rate (45.8) in the five to nine years group and lower
(3.3) in the ≥30 years age group. The cumulative inci-
dence of clinical malaria attacks is shown in Figure 3,
left panel, with 24, 108, 51, 33, and 13 clinical malaria
episodes recorded in the < five, five to nine, ten to 14,
fifteen to29 and ≥30 years age groups, respectively.
Antibody levels to PF13 and MSP1p19 at recruitment,
stratified by number of clinical malaria attacks (0 vs 1–2
vs >2) experienced during the following transmission
season are shown in Figure 3 (central and right panel,
respectively). For both antigens, a significantly lower level
of antibody response was evidenced in individuals who ex-
perienced one or more clinical attacks during the follow-
up period compared to those who experienced no clinical
malaria episode during that period.
A Poisson regression was used to analyse the relation-
ship between antibody responses and the incidence of
clinical malaria episodes during the 5.5-month period of
follow-up. The MSP1p19 or PF13 IgG levels expressed as
ELISA OD-ratio or MFI-ratio were significantly associated
with incidence of malaria attacks in univariate (monoplex
antigen) analysis (Table 3). The duplex antigen analysis
showed a significant association of malaria attack inci-
dence with IgG responses to MSP1p19 expressed as OD
values, OD-ratio or dichotomized into positive vs negative
ELISA responses (Table 3), but there was no significant
relationship with MSP1p19 MFI or MFI-ratio values or
positive vs negative dichotomized MFI-ratio. In this
analysis, antibody levels to PF13 were not associated with
incidence of malaria attacks, whatever the antibody-related
variable considered. In the age-adjusted analysis used as the
final model, where age was categorized in five classes
Figure 2 Level of IgG responses to PF13 and PfMSP1p19 measured by individual ELISA and duplex MBA. OD- and MFI-ratios of IgG
responses to PF13 and MSP1p19 are plotted as histograms (mean + SE). Antibody responses were stratified according to five age groups (<5, 5–9,
10–14, 15–29 and >30 years; symbols used range from empty, pale grey, light grey, dark grey and black, respectively). Brackets and asterisk indicate
significant differences (P <0.05) between levels of antibody responses in different age groups.
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ciated with IgG responses to MSP1p19 dichotomized into
positive vs negative ELISA responses (P = 0.01, RR = 0.71;
CI: 95% [0.53-0.93]). Dichotomisation of high vs low anti-
body responses to MSP1p19 (OD-ratio >7) [6,25] did not
show significant association with reduced number of malaria
attacks (P > 0.05). In this age-adjusted model, antibody levels
to PF13 were also unrelated to incidence of malaria attacks.
Discussion
Many sero-epidemiological data in the field of malaria have
been obtained using ELISA, including studies investigating
the association of antibody responses to one or more anti-
gens with exposure, transmission intensity and/or with pro-
tection against clinical malaria [6,25-34]. This resulted in
multiple associations of individual responses with one or
other infection outcome endpoint. Interpretation of such
studies is unclear, as indeed malaria parasites express a
large array of antigens, eliciting a large antibody repertoire
that evolves as exposure increases. Multiplex assays in the
format of protein microarrays [10-12,35,36], Luminex sys-
tem [13-16,37] allow high throughput, flexible investigation
of multiple antibody specificities in a single assay. The work
reported here aimed to be a step bridging ELISA-based
antibody monitoring with a multiplexing format. This in-
vestigation was focused on two antigens, the merozoitesurface antigen MSP1p19 and the variant erythrocyte surface
antigen PF13-DBL1a, as responses to these antigens have
been assessed using ELISA in previous sero-epidemiological
studies conducted in Senegal [6,18,24,25]. It was of interest
to know how the results obtained using both methodologies
compared for each antigen in order to be able, in future
analysis, to integrate - or not - previous ELISA results with
future multiplexing data.
A good overall correlation was found between the two
techniques. Prevalence values tended to be lower in the
MBA format than estimated from ELISA but the age-
associated distribution of antibody levels, were similar. Thus,
results found here with these two antigens confirm reports
from other groups comparing multiplex antibody measure-
ments and traditional monoplex ELISA that showed a high
degree of correlation [15,37,38]. Further, assessment of
antibody responses using the two methods did not lead to
concordant conclusions regarding the association of the
antibody responses with protection against clinical malaria
in the subsequent 5.5-month transmission season. It is im-
portant to note that the association of MSP1p19 ELISA
responses with protection observed here is consistent with
previous findings in this setting conducted in 2000,
although in previous studies protection against clinical
malaria was also associated with elevated ELISA-based OD
ratios (P <0.01, RR = 0.66 [0.51-0.86] in an age-adjusted
Table 3 Summary of univariate and multivariate Poisson regression analysis of relationship between PF13 and MSP1
antibody response with incidence rate of malaria attacks in Ndiop
Univariate individual antigen analysis PF13 and MSP1p19 adjusted model PF13 and MSP1p19 model adjusted for age
OR 95% CI P OR 95% CI P OR 95% CI P
ELISA OD
PF13 0.70 [0.6-0.9] <0.01 0.89 [0.74-1.1] 0.25 0.88 [0.7-1.1] 0.19
MSP1 0.46 [0.37-0.59] <0.01 0.49 [0.38-0.62] <0.001 0.81 [0.62-1.1] 0.12
MFI
PF13 0.99 [0.99-0.99] 0.02 0.99 [0.99-1.0] 0.12 0.99 [0.99-1.0] 0.06
MSP1 0.99 [0.99-0.99] <0.01 0.99 [0.99-0.99] <0.01 0.99 [0.99-1.0] 0.58
OD ratio
PF13 0.96 [0.94-0.98] <0.01 0.98 [0.96-1.0] 0.06 0.98 [0.96-1.0] 0.08
MSP1 0.88 [0.85-0.92] <0.01 0.89 [0.86-0.93] <0.001 0.97 [0.93-1.0] 0.13
MFI ratio
PF13 0.98 [0.97-0.99] 0.02 0.99 [0.9-1.0] 0.11 0.98 [0.97-1.0] 0.06
MSP1 0.95 [0.93-0.97] <0.01 0.95 [0.93-0.98] <0.01 0.99 [0.96-1.0] 0.52
Dichotomized antibody response according to OD ratio threshold
PF13 positivity 0.79 [0.60-1.04] 0.10 0.98 [0.74-1.30] 0.90 1.2 [0.86-1.6] 0.30
MSP1 positivity 0.44 [0.34-0.57] <0.01 0.44 [0.33-0.57] <0.001 0.71 [0.53-0.93] 0.01
Dichotomized antibody response according to MFI Ratio threshold
PFf13 positivity 0.83 [0.63-1.1] 0.17 1.01 [0.7-1.4] 0.91 1.08 [081–1.45] 0.57
MSP1 positivity 0.61 [0.47-0.79] <0.01 0.61 [0.4-0.8] <0.001 0.89 [0.67-1.18] 0.43
Dichotomized antibody response according with ROC threshold
PF13 positivity 0.70 [0.5-0.9] 0.03 0.89 [0.7-1.2] 0.48 1.1 [0.8-1.5] 0.48
MSP1 positivity 0.78 [0.60-1.02] 0.07 0.82 [0.6-1.1] 0.21 1.05 [0.78-1.4] 0.75
Figure 3 Incidence of clinical malaria attacks during the 5.5-month follow-up and its relationship to levels of antibody responses
against PF13 and MSP1p19. The left panel shows the mean incidence of malaria attacks by age group. The middle and right panels show OD-ratios
(black) and MFI-ratios (grey) values of antibody responses to PF13 or MSP1p19 plotted as histograms (+SE) by occurrence of clinical attacks in the
follow-up period stratified as 0 vs 1–2 vs >2 confirmed clinical malaria attacks. The number of individuals in each stratified group was 107 (mean age
32.5 [3.9-76.9]), 76 (mean age 19.4 [3.7-74.6]), 34 (mean age 8.7 [3.4-16.1]) with 0 vs 1–2 vs >2 clinical attacks, respectively. Brackets and asterisk indicate
significant differences (P < 0.05) between antibody responses in different categories.
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IgG responses (dichotomized OD ratios >7) and protection
against clinical malaria was not found here, possibly
related to the different level of transmission resulting in
lower antibody boosting (17.9 infective bites/individual in
2002 vs 50.75 in 2000).
The discrepant association of ELISA and MBA readouts
with protection is of concern for analysis aiming at com-
bining data from different studies using one or the other
methodology. In the present work, it may result from the
relatively limited size of the susceptible age groups in the
cohort studied, resulting in non-reproducible association
with individual antibody-level readouts. It may however
reflect an important intrinsic difference, namely that both
formats display incompletely overlapping sets of epitopes.
This is not unexpected as covalent cross-linking to the
beads and adsorption to the plastic wells impact differently
on the panel of epitopes displayed. As a consequence, anti-
body specificities captured do not fully overlap in the two
systems, translating into an imperfect correlation of anti-
body levels measured by both technologies (Rho = 0.74 in
the case of MSP1p19). Whether some of protection-
associated epitopes of MSP1p19 are exposed in the ELISA
assay while masked in the MBA format definitely needs to
be further explored. In addition, it is worth recalling that a
large body of data indicates that association with protection
is more accurately investigated using functional tests, such
as growth inhibition assays [39,40], ADCI [41] or neutro-
phil respiratory burst [42] than using simple antibody-level
measures. It is possible that antibody investigation using
individual antigens or multiplex formats is better suited to
analysis of antigenicity in human populations and of
dynamics of responses in different endemic conditions.
There was no association of any of the PF13 antibody
response read out with protection against clinical mal-
aria. This is not surprising as PF13-0003, the variant
antigen from which PF13 is derived, is merely one
amongst a large array of variant surface antigens that
elicit a variant-specific surface seroreactivity [18] and
hence probably variant-specific protection. It is thus
predicted that antibody to PF13 would be protective
against PF13 and closely related variants but not against
unrelated variants (i.e. the great fraction of the var rep-
ertoire). To properly define protection afforded by anti
PF13 antibody, analysis of the var genes expressed by
superinfecting parasites is needed to demonstrate that
these do not include PF13/PF13-like genes. This could
not be done because parasites were not appropriately
collected for ribonucleic acid (RNA) extraction. Never-
theless, data are consistent with the current view that
antibody to PF13 are acquired by young children at the
time they experience numerous infections displaying a
large array of antigens, including a wide repertoire of
PfEMP1 antigens.The age distribution of seroprevalence and levels of anti-
body to MSP1p19 in the 2002 survey are in line with obser-
vations made in a previous cross-sectional survey conducted
in Ndiop in 2000 showing 79% of responders [6]. With
regard to antibodies to PF13, the age distribution in this
meso-endemic setting differs from that in the nearby village
of Dielmo, where malaria is holo-endemic [18]. In Dielmo,
seroprevalence was high (99.1% as assessed by ELISA on
PF13) and seroconversion occurred before the age of five
years. In contrast, a seroprevalence of 71% (as assessed by
ELISA) was observed here in Ndiop, and seroconversion
occurred over a much longer time period, namely the first
14 years of life. Thus, there is a clear age shift in the acquisi-
tion of antibody to PF13 in Ndiop compared to Dielmo. This
is consistent with the differing transmission conditions in
both settings, the EIR being five to ten-fold lower in Ndiop
than in Dielmo, and transmission being restricted over a few
months in Ndiop while being perennial in Dielmo.
Interestingly, a bell-shape distribution of antibody to
PF13 by age was observed, with adult individuals having
lower antibody levels than older children. This confirms
previous observations in Dielmo [18]. Such age-distribution
of IgG responses can be interpreted as indicating limited
boosting of the PF13 response by infections in older indi-
viduals, as i) only a small fraction of each parasite inoculum
expresses PF13; and, ii) anti PF13 antibody would readily
eliminate PF13- and PF13-related variants. This differs from
the continuous increase in antibody levels observed for
MSP1-P19 as people get older. In this case, the whole in-
oculum of the successive parasite infections expresses this
well-conserved and abundant antigen, probably triggering
frequent boosting.
Conclusion
This duplex pilot study provided important information for
future work. Although there was a strong overall concord-
ance of responses between both methodologies, there was a
clear difference when analysing the association with protec-
tion, possibly reflecting partial overlap of displayed epitopes.
Merging data generated in previous studies using ELISA
with future studies using the MBA format needs to be done
with some caution. This work indicates that MBA is a ro-
bust and cost-effective approach for seroprevalence studies,
expression of results for antibody responses can be con-
veniently done using MFI values and calls for expanding
the antigen array in future studies.
Additional file
Additional file 1: Age distribution of IgG responses to PF13 and
PfMSP1p19 expressed as OD for ELISA and MFI for MBA. OD and
MFI values of IgG responses to PF13 and MSP1p19 are plotted as
histograms (mean + SE). Antibody responses were stratified according to
five age groups (<5, 5–9, 10–14, 15–29 and >30 years; symbols used
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